Clinical Trials
129 trialsNCT04331067 2026-05-06
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT02734290 2026-04-24
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT05108870 2026-04-24
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
University of Chicago
Phase 1/2 Active not recruiting
NCT01980277 2026-04-21
TAKTIC
Institut Paoli-Calmettes
Phase 1/2 Terminated
NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05383196 2026-02-11
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT06207305 2026-01-13
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT02726997 2025-12-18
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT05381038 2025-09-23
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT06543576 2025-08-15
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05275777 2025-07-25
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT02713386 2025-05-25
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 1/2 Completed
NCT03871036 2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT06494943 2025-02-25
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Fudan University
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT03616886 2024-12-19
SYNERGY
Jules Bordet Institute
Phase 1/2 Active not recruiting
NCT05640830 2024-11-26
TREAZURE
Kangbuk Samsung Hospital
Phase 1/2 Recruiting
NCT03356860 2024-11-20
B-IMMUNE
Grand Hôpital de Charleroi
Phase 1/2 Completed
NCT02938442 2024-11-07
Vaccination of Triple Negative Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting
NCT03490292 2024-07-26
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT03126812 2024-05-29
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT05529667 2024-05-08
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.
Yonsei University
Phase 1/2 Completed
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT06303583 2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2 Enrolling by invitation
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT02735057 2024-01-18
OSAGE
Centre Hospitalier Universitaire de Besancon
Phase 1/2 Recruiting
NCT03618758 2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2 Completed
NCT05400915 2023-11-13
Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Yonsei University
Phase 1/2 Completed
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02530437 2023-07-10
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT03544736 2023-03-22
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Oslo University Hospital
Phase 1/2 Active not recruiting
NCT05535569 2022-09-10
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
Yonsei University
Phase 1/2 Completed
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting
NCT05394415 2022-05-27
LATE
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT03278626 2022-03-28
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NYU Langone Health
Phase 1/2 Terminated
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT00618917 2021-11-12
MnSOD
University of Pittsburgh
Phase 1/2 Terminated
NCT01757288 2021-10-28
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT04526470 2021-08-24
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
Seoul National University Bundang Hospital
Phase 1/2 Unknown